Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6709)	1/15/1999 2:53:00 PM
From: BigKNY3	Read Replies (1) \| Respond to of 9523

Nastech Comments on Stock Volatility HAUPPAUGE, N.Y., Jan. 15 /PRNewswire/ -- In response to investor inquiries, Nastech Pharmaceutical Company, Inc. (Nasdaq: NSTK - news) said today's sharp movement in the company's shares may be due to some investors making an erroneous connection between the company and recent publicity from the University of Kentucky on the development of an intranasal form of Viagra. Nastech said it knows of no other reason for the volatility of its shares. Nastech previously licensed several nasally administered compounds from the university. Nastech previously announced it is independently studying the feasibility of two compounds for treatment of erectile dysfunction. Nastech is recognized worldwide as the foremost leader in nasal drug delivery. The company has R&D collaborations and commercial partnerships with several major pharmaceutical companies, including Bristol-Myers Squibb and Schwarz Pharma, among others. The company has expanded its proprietary franchise in nasal technology to include 12 patents covering the nasal delivery of 67 compounds and 4 additional patents pending. This press release may contain forward-looking statements that reflect the company's intentions, expectations or beliefs concerning future events, including, but not limited to, expectations with respect to FDA approval of new products, technology and product development milestones, the ability of the company to leverage its product development and negotiate favorable collaborative agreements, the commencement of sales and the sufficiency of the company's cash flow for future liquidity and capital resource needs. The forward-looking statements are qualified by important factors that could cause actual results to differ materially from those in the forward-looking statements. In addition, significant fluctuations in quarterly results may occur as a result of varying milestone payments and the timing of costs and expenses related to the company's research and development programs. SOURCE: Nastech Pharmaceutical Company, Inc.